Meeting
2021 ASCO Annual Meeting
Gene expression signature to predict radiation response in lower-grade gliomas.
Authors
David C Qian
Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA
David C Qian , Joseph A. Marascio , Stewart G. Neill , Kimberly B. Hoang , Jeffrey J. Olson , Bree R. Eaton , Hui-Kuo George Shu , Jim Zhong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2019)
DOI
10.1200/JCO.2021.39.15_suppl.2019
Abstract #
2019
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Aggressive treatment and survival outcomes in NUT midline carcinoma (NMC) of the head and neck (HN).
First Author: Nicole Grace Chau
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 1b/II study of durvalumab (D) and tremelimumab (T) plus PET-adjudicated chemoradiation (CRT) in patients (Pts) with esophageal adenocarcinoma.
First Author: Geoffrey Yuyat Ku
Poster
2022 ASCO Annual Meeting
CCTG BL13 a randomized phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer (NCT03768570).
First Author: Wassim Kassouf
Poster
2020 ASCO Virtual Scientific Program
Long-term analysis of the WHO-defined molecular subgroups of high-risk grade II gliomas treated with radiation and temozolomide on NRG Oncology/RTOG 0424.
First Author: Erica Hlavin Bell